QMI
- 产品代码
- QMI
- 器械名称
- Nucleic Acid Amplification Test For The Quantitation Of Bk Virus (Bk) Dna
- 管理类别
- 第 2 类(Class II)
- 21 CFR 条款
- 21 CFR 866.3183
- FDA 专业组
- Microbiology
- 上市路径
- 需提交 510(k) 上市前通告
- 该代码近三年的 510(k)
- 1 件
- 其中 Summary 已存档
- 1 份,可直接下载
- FDA 历史累计 510(k)
- 2 件(全部年份;本站只收录近三年的明细)
FDA 分类定义
An in vitro nucleic acid amplification test for the quantitation of BK virus (BKV) DNA in human samples intended for use as an aid in the management of BKV in transplant patients. In patients undergoing monitoring of BKV, serial DNA measurements can be used to indicate the need for potential treatment changes and to assess viral response to treatment. Test results are intended to be read and analyzed by a qualified licensed healthcare professional in conjunction with clinical signs and symptoms and relevant laboratory findings. Test results must not be the sole basis for patient management decisions.
该代码近三年的 510(k)(1 件)
| 510(k) 号 | 批准日期 | 申请人 | 器械名称 | 摘要 |
|---|---|---|---|---|
| K241921 | 2025-03-24 | Abbott Molecular, Inc. | Alinity m BKV |
FDA 官方分类页: QMI
分类与上市路径以 FDA 现行公告为准。本页数据来自 openFDA(CC0 公有领域),不构成注册策略建议。